ebola virus glycoprotein nanoparticle vaccine

The Ebola virus glycoprotein nanoparticle vaccine (NVX-EBOV2510) is a recombinant protein subunit vaccine developed by Novavax. It utilizes Novavax's proprietary recombinant nanoparticle technology, where the Ebola virus glycoprotein (GP) is expressed in a baculovirus/Sf9 insect cell system and assembled into stable protein nanoparticles. The vaccine is typically administered alongside the Matrix-M adjuvant, a saponin-based formulation designed to enhance the magnitude and durability of the immune response by stimulating both humoral and cellular pathways. Clinical development has focused on safety and immunogenicity in healthy adults, demonstrating the induction of high levels of anti-GP neutralizing antibodies.

Other names

Ebola GP nanoparticle vaccineNovavax Ebola vaccineEBOV GP vaccine